Your shopping cart is currently empty

D3S-001 is an orally effective KRAS inhibitor. It suppresses the proliferation of the KRASG12C mutants H358 and MIA-PA-CA-2 with IC50 values of 0.6 and 0.44 nM, respectively. D3S-001 exhibits good metabolic stability across multiple species in hepatocytes, liver microsomes, plasma, and whole blood. Additionally, it demonstrates favorable pharmacokinetic properties and antitumor activity in mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | D3S-001 is an orally effective KRAS inhibitor. It suppresses the proliferation of the KRASG12C mutants H358 and MIA-PA-CA-2 with IC50 values of 0.6 and 0.44 nM, respectively. D3S-001 exhibits good metabolic stability across multiple species in hepatocytes, liver microsomes, plasma, and whole blood. Additionally, it demonstrates favorable pharmacokinetic properties and antitumor activity in mice. |
| Molecular Weight | 679.66 |
| Formula | C32H35F6N7O3 |
| Cas No. | 2914919-85-8 |
| Smiles | C(OC1=NC(=C2C(=N1)C[C@H](OC2)C3=C(C(F)(F)F)C(C)=CC(N)=C3F)N4C[C@H](CC#N)N(C(C(=C)F)=O)CC4)[C@@]56N(C[C@H](F)C5)CCC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.